ADX-097 in IgA Nephropathy, Lupus Nephritis, or C3 Glomerulopathy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2 interventional trial evaluating the safety, pharmacodynamics, pharmacokinetics, and clinical activity of ADX-097 given by subcutaneous injection. Eligible participants include adults and adolescents with IgA nephropathy, lupus nephritis, or C3 glomerulopathy, meeting kidney function and biomarker criteria. Participants may be taking stable doses of certain kidney disease medications, with eligibility requiring consistent regimens through the study. The study actively monitors kidney-specific outcomes and systemic safety, aiming to identify signals of efficacy across the included conditions. Locations include sites in Georgia, Florida, and South Carolina, under Akebia Therapeutics as lead sponsor.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

All participants

1. Male or female participants aged ≥16 years.
2. uPCR ≥0.5 g/g (from the average of 3 first morning voids \[FMVs\]).
3. Screening eGFR ≥30 mL/min/1.73m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation (CKD-EPI GFR).
4. Participants receiving a renin-angiotensin-aldosterone system (RAAS) inhibitor, sodium-glucose cotransporter-2 (SGLT2) inhibitor, sparsentan, or atrasenten must have been on a stable dose (at the maximum recommended dose according to local guidelines or maximum tolerated dose) for at least 8 weeks prior to Study Day 1 and the dose is projected to remain stable until completion of the study.

   Participants with IgAN only
5. Kidney biopsy-proven diagnosis of IgAN with a kidney biopsy that is obtained within 10 years of Day 1 or within 5 years of Day 1 if the participant is known or suspected of also having diabetic nephropathy.

   Participants with LN only
6. Clinical diagnosis of systemic lupus erythematosus (SLE)
7. Kidney biopsy-proven diagnosis of LN with a kidney biopsy that is obtained within 24 weeks of Day 1.
8. Diagnosis of active focal or diffuse LN class III or IV

   Participants with C3G only
9. Kidney biopsy-proven diagnosis of C3G, either dense deposit disease (DDD) or complement component 3 glomerulonephritis (C3GN), with a kidney biopsy that is obtained within 52 weeks of Day 1.
10. Participants receiving mycophenolate mofetil (MMF) (or mycophenolic acid) or prednisone ≥10 mg/d or equivalent must have been on a stable dose for at least 12 weeks before Day 1 that is projected to remain stable until completion of the study.

Key Exclusion Criteria All participants

1. Rapidly progressive glomerulonephritis defined as a 50% decline in eGFR within 12 weeks of screening.
2. Concomitant significant renal disease other than IgAN, C3G, or LN per investigator discretion.
3. Participants with a history of and/or presence of anti-factor H antibodies at screening.
4. Uncontrolled hypertension with mean seated systolic blood pressure (BP) ≥160 mmHg or diastolic BP ≥100 mmHg based on the average of 2 measurements obtained at approximately 2-minute intervals after the individual has been sitting for 5 minutes.
5. Kidney, other solid organs, or bone marrow transplantation prior to or expected to occur during the study.
6. History of splenectomy.

   Participants with IgAN only
7. Secondary forms of IgAN
8. Received systemic corticosteroid therapy, oral budenoside, or any other form of immunosuppressive therapy within 12 weeks before Day 1.

   Participants with LN only
9. Lymphocyte count below 0.5 × 109/L at screening.
10. Received any of Cyclophosphamide, Calcineurin inhibitors, IV methylprednisolone, IV immunoglobulin therapy, Belimumab, Obinutuzumab and Rituximab treatments at protocol specified time points.

    Participants with C3G only
11. Evidence of monoclonal gammopathy of unclear significance, infections, malignancy, autoimmune diseases, or other conditions to which C3G is secondary.
12. Received systemic corticosteroid therapy, eculizumab, iptacopan, pegcetacoplan, or any other form of immunosuppressive therapy ≤12 weeks before Day 1, except for MMF (or mycophenolic acid), which is permitted.

Where it's running

• Investigator Site #3
  Hollywood, Florida, United States Recruiting
• Investigator Site #1
  Lawrenceville, Georgia, United States Recruiting
• Investigator Site #4
  Orangeburg, South Carolina, United States Recruiting
• Investigator Site #2
  São Paulo, Brazil Not yet recruiting

Study contacts

• Study coordinator: Akebia Therapeutics
• Email: trials@akebia.com
• Phone: 16178446128

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TranspoCART19 CAR-T therapy in adults with refractory lupus nephritis

  This trial tests whether a patient’s own CD19 CAR-T cells can be safely given and potentially help adults with lupus nephritis that isn’t responding to standard treatments.

  Recruiting Phase 1/2 Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Badalona, Barcelona and 7 other locations · NCT07799116

• Lupus Nephritis Care Pathway

  A small group of adults with lupus nephritis will try a team-based care path that uses telemedicine and pharmacist-led support to help manage their treatment and see if it improves adherence and outcomes.

  Recruiting Duke University · Durham, North Carolina · NCT07783152

• Initial glucocorticoid-dose harmonization in childhood lupus nephritis

  This trial tests whether starting children with Lupus Nephritis on a lower or higher prednisone dose makes a difference in treatment outcomes.

  Recruiting at 2 sites Phase 4 Peking Union Medical College Hospital · Beijing, Beijing Municipality and 7 other locations · NCT07719140

• See if empagliflozin helps kidney function in people with lupus nephritis

  This study tests whether adding empagliflozin to standard care improves kidney function in adults with active lupus nephritis.

  Recruiting Phase 4 Beni-Suef University · Banī Suwayf · NCT07700940

• JADE101 in IgA Nephropathy: a Phase 2 test in adults

  This Phase 2 open-label study tests JADE101 in adults with IgA nephropathy to see how safe it is and how well it works when added to standard care.

  Recruiting at 22 sites Phase 2 Jade Biosciences, Inc. · Chula Vista, California and 21 other locations · NCT07541287

• Atrasentan for pediatric primary IgA nephropathy

  This study tests whether atrasentan can help children and teens with primary IgA nephropathy reduce protein in urine.

  Recruiting at 19 sites Phase 3 Novartis · Neptune City, New Jersey and 22 other locations · NCT07498335

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.